JP2004526745A - 体脂肪を減らし脂肪酸の代謝を変調する方法、化合物および組成物 - Google Patents

体脂肪を減らし脂肪酸の代謝を変調する方法、化合物および組成物 Download PDF

Info

Publication number
JP2004526745A
JP2004526745A JP2002578899A JP2002578899A JP2004526745A JP 2004526745 A JP2004526745 A JP 2004526745A JP 2002578899 A JP2002578899 A JP 2002578899A JP 2002578899 A JP2002578899 A JP 2002578899A JP 2004526745 A JP2004526745 A JP 2004526745A
Authority
JP
Japan
Prior art keywords
fatty acid
composition
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002578899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526745A5 (enExample
Inventor
ダニエル ピオメリ，
フォンセカ， フェルナンド ロドリゲズ デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2004526745A publication Critical patent/JP2004526745A/ja
Publication of JP2004526745A5 publication Critical patent/JP2004526745A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2002578899A 2001-03-27 2002-03-27 体脂肪を減らし脂肪酸の代謝を変調する方法、化合物および組成物 Pending JP2004526745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US33628901P 2001-10-31 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (2)

Publication Number Publication Date
JP2004526745A true JP2004526745A (ja) 2004-09-02
JP2004526745A5 JP2004526745A5 (enExample) 2005-12-22

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578899A Pending JP2004526745A (ja) 2001-03-27 2002-03-27 体脂肪を減らし脂肪酸の代謝を変調する方法、化合物および組成物

Country Status (11)

Country Link
US (3) US6911474B2 (enExample)
EP (1) EP1408945A4 (enExample)
JP (1) JP2004526745A (enExample)
KR (1) KR20030087657A (enExample)
CN (1) CN1523982A (enExample)
AU (1) AU2002338329B2 (enExample)
CA (1) CA2442683A1 (enExample)
EA (1) EA006556B1 (enExample)
IL (1) IL158131A0 (enExample)
MX (1) MXPA03008823A (enExample)
WO (1) WO2002080860A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521914A (ja) * 2008-05-19 2011-07-28 ネステク ソシエテ アノニム 動物による脂質吸収を抑制する方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
EP1482920B2 (en) † 2002-02-12 2011-07-20 Hunza di Pistolesi Elvira & C. S.a.S. Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
US20040157932A1 (en) * 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
JP2007509066A (ja) * 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
EP1570752B1 (en) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20090054526A1 (en) * 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NZ571110A (en) * 2006-04-11 2011-03-31 Arena Pharm Inc Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
WO2009033050A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth Sys Tem Of Higher Education Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
AU2011229969A1 (en) * 2010-03-24 2012-09-20 Nestec S.A. Methods for enhancing the palatability of comestible compositions
BR112013000045A2 (pt) 2010-07-02 2016-05-10 Helix Biomedix Inc derivados de aminoácido n-acil para o tratamento de condições cutâneas como celulite
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
WO2012154711A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
BR112013028759A2 (pt) * 2011-05-10 2016-08-09 Nestec Sa métodos e composições para conservar a massa magra do corpo durante a perda de peso
US8426471B1 (en) * 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
JP2015534544A (ja) 2012-09-07 2015-12-03 ネステク ソシエテ アノニム オレオイルエタノールアミド組成物
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
SG11201600237YA (en) 2012-11-21 2016-02-26 Topokine Therapeutics Inc Methods and compositions for locally increasing body fat
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2001089589A1 (en) 2000-05-23 2001-11-29 The Regents Of The University Of California A novel treatment for cough
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
EP1372638B1 (en) * 2001-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Cannabinoids for the treatment of breathing disorders during sleep
EP1419237A4 (en) * 2001-07-31 2005-12-21 Scripps Research Inst ANIMAL MODEL FOR NEURO BEHAVIOR IN CONNECTION WITH FATTY ACID AMIDES
PL373970A1 (en) 2002-02-08 2005-09-19 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
US20040157932A1 (en) 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521914A (ja) * 2008-05-19 2011-07-28 ネステク ソシエテ アノニム 動物による脂質吸収を抑制する方法

Also Published As

Publication number Publication date
WO2002080860A2 (en) 2002-10-17
CA2442683A1 (en) 2002-10-17
KR20030087657A (ko) 2003-11-14
US20030018081A1 (en) 2003-01-23
AU2002338329C1 (en) 2002-10-21
WO2002080860A3 (en) 2004-02-26
EP1408945A4 (en) 2005-07-06
US20090005447A1 (en) 2009-01-01
EA006556B1 (ru) 2006-02-24
MXPA03008823A (es) 2004-08-12
US20050187254A1 (en) 2005-08-25
US7423066B2 (en) 2008-09-09
CN1523982A (zh) 2004-08-25
US6911474B2 (en) 2005-06-28
EA200301057A1 (ru) 2004-04-29
AU2002338329B2 (en) 2006-09-07
IL158131A0 (en) 2004-03-28
EP1408945A2 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
AU2002338329B2 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2002338329A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
JP2007509066A (ja) 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
Irwin et al. Basic physiological effects of ketamine-xylazine mixture as a general anesthetic preparation for rodent surgeries
US20050101542A1 (en) Combination therapy for controlling appetites
AU2010306114B2 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
US11147820B2 (en) Methods for treating GI tract disorders
ES2659763T3 (es) Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
EP3568138B1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
Azzena et al. Nitric oxide regenerates the normal colonic peristaltic activity in mdx dystrophic mouse
US20240197756A1 (en) Methods of treatment with neuroactive steroids
US20050054730A1 (en) Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US9844554B2 (en) Prodrugs of metopimazine
BR112020011401A2 (pt) combinação de moduladores de receptor nmda (rapastinel) para uso em tratamento combinado (distúrbio do sono e do snc)
CN105503741A (zh) 一种氨基甲酰尿嘧啶衍生物及其应用
Muntzel et al. Dietary salt loading exacerbates the increase in sympathetic nerve activity caused by intravenous insulin infusion in rats
BR102021010256A2 (pt) Uso do derivado (4-(3,5-di-tert-butil-4- hidroxibenzilamino)benzenesulfonamida) lqfm275 como analgésicos e/ou anti-inflamatórios e sais farmaceuticamente aceitáveis, composições farmacêuticas contendo os mesmos e processos de preparação
JP2020516602A (ja) 環状プラスメニルエタノールアミン
EP3478279A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
Sagona Optical imaging and automated behavior as tools for the diagnostic monitoring of brain function in neurodevelopmental disorders
PT100759A (pt) Composicoes farmaceuticas para o tratamento do sindroma premenstrual contendo um inibidor do enzima conversor da angiotensina
Ádám et al. Second Joint Meeting of the LXXIV Annual Meeting of the Hungarian Physiological Society and the Hungarian Society for Experimental and Clinical Pharmacology
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途
BR122023014342B1 (pt) Compostos análogos de celastrol, composição farmacêutica compreendendo ditos compostos e usos dos mesmos para tratar obesidade ou uma doença ou distúrbio relacionado à obesidade
HK1173379B (en) Compositions comprising tramadol and celecoxib in the treatment of pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090625